Background To date there are no biomarkers with proven reliability as a measure of disease
burden in amyotrophic lateral sclerosis ( ALS ). The aim of our study is to assess the …

… ) HFMSE scores and (D–F) RULM scores across time points. Data for SMA2 are shown in
panels A and D, while data for SMA3 sitters are shown in panels B and E, and those for SMA3 ‘…

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease.
While genetics and other factors contribute to ALS pathogenesis, critical knowledge is still …

Amyotrophic lateral sclerosis (ALS) has heterogeneous clinical features that could be
translated into specific patterns of brain atrophy. In the current study we have evaluated the …

Background and purpose To evaluate whether cerebrospinal fluid ( CSF ) neurofilament light
chain ( NFL ) levels could predict the time to generalization ( TTG ) in amyotrophic lateral …

Background and purpose Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective …

Objective The aim of this study was to provide an overview of the clinical phenotypes associated
with 4 SMN2 copies. Methods Clinical phenotypes were analyzed in all the patients with …

Doctoral education requires academic motivation and persistence on the part of nursing
students; commitment to the process is essential and should be linked to programmatic structure…

Urate is a natural antioxidant, and high serum urate levels could be protective against the
development of amyotrophic lateral sclerosis (ALS). To determine if serum urate …

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that
still lacks reliable diagnostic biomarkers. This study aims to evaluate the diagnostic and …